Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.16%
#2 0G 0G +29.67%
#3 Nockchain Nockchain +23.93%
#4 Zora Zora +23.55%
#5 Fake World Assets Fake World Assets +19.22%
#6 Full Moon Full Moon +17.70%
#7 Axelar Axelar +17.49%
#8 Notcoin Notcoin +16.89%
#9 ADO Protocol ADO Protocol +15.48%
#10 SAFEcoin SAFEcoin +13.35%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

3378
Rang in aandelen #13048
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and... Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Aandeelprijs
$3.91
Marktkapitalisatie
$524.79M
Verandering (1 dag)
-0.71%
Verandering (1 jaar)
-
Land
CN
Handel Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Categorie

Healthcare
Dividendgeschiedenis van Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (aandelsymbool: 3378) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH